
==== Front
Cancer Immunol Immunother
Cancer Immunol Immunother
Cancer Immunology, Immunotherapy : CII
0340-7004
1432-0851
Springer Berlin Heidelberg Berlin/Heidelberg

39105816
3776
10.1007/s00262-024-03776-5
Brief Report
GP100 expression is variable in intensity in melanoma
Mann Jacqueline E. 1
Hasson Nitzan 1
Su David G. 2
Adeniran Adebowale J. 3
Smalley Keiran S. M. 4
Djureinovic Dijana 1
Jilaveanu Lucia B. 1
Schoenfeld David A. 1
Kluger Harriet M. Harriet.kluger@yale.edu

1
1 https://ror.org/03v76x132 grid.47100.32 0000 0004 1936 8710 Division of Medical Oncology, Yale University School of Medicine, New Haven, CT USA
2 https://ror.org/03v76x132 grid.47100.32 0000 0004 1936 8710 Division of Surgical Oncology, Yale University School of Medicine, New Haven, CT USA
3 grid.47100.32 0000000419368710 Department of Pathology, Yale University School of Medicine, New Haven, CT USA
4 https://ror.org/01xf75524 grid.468198.a 0000 0000 9891 5233 Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL USA
6 8 2024
6 8 2024
10 2024
73 10 19121 5 2024
5 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Drugs or cellular products that bind to gp100 are being investigated for treatment of cutaneous melanoma. The relative specificity of gp100 expression in melanocytes makes it an attractive target to harness for therapeutic intent. For example, Tebentafusp, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has generated significant enthusiasm in recent years due to its success in improving outcomes for uveal melanoma and is being studied in cutaneous melanoma. However, the extent and intensity of gp100 expression in advanced cutaneous melanoma has not been well studied. Here, we interrogated a large cohort of primary and metastatic melanomas for gp100 expression by immunohistochemistry. Expression in metastatic samples was globally higher and almost uniformly positive, however the degree of intensity was variable. Using a quantitative immunofluorescence method, we confirmed the variability in expression. As gp100-binding drugs are assessed in clinical trials, the association between activity of the drugs and the level of gp100 expression should be studied in order to potentially improve patient selection.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00262-024-03776-5.

Keywords

Glycoprotein 100
ImmTAC
Melanoma
Targeted therapy
Tebentafusp
NIH1T32AI155387-01A1 1R01CA269349 Mann Jacqueline E. Schoenfeld David A. issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

While immune checkpoint inhibitors (ICIs) have dramatically improved treatment for advanced melanoma, responses vary across disease subtypes. Uveal melanoma accounts for 3–5% of melanomas and carries a worse prognosis, with median overall survival of less than one year in metastatic disease [1–3]. Further, while ICI regimens have substantially improved outcomes in metastatic cutaneous melanoma, they are less effective in metastatic uveal melanoma, which exhibits distinct molecular characteristics including lower mutational burden and lower PD-L1 expression [4, 5]. This disparity has spurred an ongoing effort to explore novel strategies tailored for uveal melanoma. The glycoprotein 100 (gp100) is reported to be expressed in 63–90% of melanomas [6, 7] and has long been of interest as a potential therapeutic target, leading to numerous targeted therapy trials including gp100-targeted vaccines and adoptive cell transfer. Despite occasional promising results in small-scale initial trials, gp100 targeting therapies have historically not yielded survival benefit in larger randomized trials [8–10]. More recently, a first-in-class immune-mobilizing monoclonal T-cell receptor against cancer (ImmTAC), Tebentafusp, has been developed [10]. Tebentafusp is a bispecific fusion protein comprised of an HLA-A*02:01- restricted T cell receptor that recognizes gp100 and an anti-CD3 single chain variable fragment, allowing recruitment and activation of T cells upon binding to gp100-expressing target cells [11]. A randomized trial investigated tebentafusp in uveal melanomas and demonstrated a significant improvement in overall survival compared to a control group receiving investigator’s choice of single-agent pembrolizumab, ipilimumab, or dacarbazine (21.6 months in the tebentafusp group vs 16.9 months in the control group) [11]. This result led to the 2022 approval of tebentafusp by the Food and Drug Administration for treatment of metastatic uveal melanoma in HLA-A*02:01-positive patients [12].

Given that five-year overall survival rates are > 52% with ICI in half of cutaneous melanoma patients [13–15], expanding trials of tebentafusp to the cutaneous melanoma setting is of great interest. Tebentefusp is currently being studied in a randomized trial with or without pembrolizumab in patients with non-uveal melanoma (NCT05549297). Therefore, a more nuanced understanding of gp100 expression levels and their impact on treatment response might enable clinicians to improve response rates by preferentially treating those more likely to respond. As an initial step toward this goal, the present study directly compares gp100 expression across a panel of cutaneous and uveal melanoma cell lines and interrogates the range of gp100 expression in cutaneous melanoma specimens and nevi.

Methods

Human cell lines

Yale University (YU)-designated cell strains were derived from human tumors as described [16]. Ten low-passage (< 20) melanoma cultures were obtained from the Biospecimen Core of the Yale SPORE in Skin Cancer (Table S1). All YU-designated cell lines were maintained in OptiMEM media (Invitrogen) supplemented with 10% heat-inactivated FBS (Invitrogen) and 1% antibiotic-antimycotic (penicillin, streptomycin, amphotericin B). Uveal melanoma cell lines 92.5, OMM1, MP38, Mel202, Mel270, Mel290, and MP41 were provided by Dr. Keiran Smalley and maintained in RPMI supplemented with 10% FBS, 1% Penicillin-Streptomycin, and 1% Non-essential amino acids. Cells were incubated at 37 °C in a humidified atmosphere of 95% air/5% CO2. Mutation status for BRAF and NRAS was retrieved from the DepMap portal (https://depmap.org/portal) for non-YU uveal melanoma cell lines.

Western blotting

Western blotting was performed by standard methods. For gp100 detection we used monoclonal rabbit anti-human gp100 (Novus) diluted at 1:1000. Quantitation was done using Image J.

Patient cohort and tissue microarray construction

The melanoma and nevi tissue microarrays were constructed as previously described [17, 18]. Collection of patient specimens and clinical data was approved by the Yale University Institutional Review Board. Representative regions of invasive tumor were examined by a pathologist and a 0.6 mm diameter core was obtained from the tumor region for each specimen. Cores from 230 primary melanomas and 293 metastatic melanomas resected between 1959 and 2000 were arranged in a tissue microarray. Of these, 119 primary tumors and 209 metastases had sufficient viable tumor tissue for analysis. Patients were 55% male with age of diagnosis ranging from 18 to 91 years (mean = 52.4 years), and follow-up ranged from 2 months to 40 years (mean = 6.7 years). Anatomic sites of metastatic lesions included lymph node (48%), skin (32%), abdominal viscera (7.2%), bone (3.0%), and lung (3.0%). Other sites (breast, brain, nasal/oral mucosa, muscle, pericardium, and pleura) were each represented by < 1% of metastatic cores. BRAFV600E staining was positive in 64% of cores [19]. The nevus array contains cores from 263 benign lesions as well as 40 metastatic or primary specimens also represented on the melanoma array. Both arrays contained identical cell lines, cored from pellets. Overlapping metastatic and primary specimens and cell lines were used for normalization of the scores obtained from the benign and malignant arrays.

Immunohistochemistry

For immunohistochemistry (IHC), 5 µm TMA sections were mounted on glass slides, incubated with 0.5% bovine serum albumin in tris buffered saline for 30 min, and incubated at 4 °C overnight slides with the antibody HMB45 (BioGenex diluted 1:250). Slides were incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Envision) for 2 h at room temperature and stained with 3-Amino-9-Ethylcarbazole (AEC) substrate solution (Abcam ab64252; red stain) and hematoxylin per manufacturer’s instructions. Immunohistochemistry staining was evaluated by an independent pathologist (A.A) blinded to the clinical data. Tissue staining was largely uniform within the histospots and were therefore scored on a scale of 0–3 for negative, weak, moderate and strong staining.

Immunofluorescence

Immunofluorescence staining was performed as previously described [17]. Slides were incubated with the HMB45 antibody (BioGenex) diluted at 1:250 at 4 °C overnight. Anti-rabbit horseradish peroxidase-conjugated secondary antibody (Envision) was applied for signal amplification and Cy5-tyramide (NED Life Science Products) was used for visualization of gp100. To distinguish tumor from stroma, slides were incubated with mouse anti-S100 at 1:100 (ThermoFisher, clone 15E2E2). Cy3-tyramide (NED Life Science Products) was used for visualization of S100. Slides were incubated with 4,6-diamidine-2-phenylin- dole (DAPI, 1:200, Invitrogen, Carlsbad, CA) for nuclear staining.

Monochromatic images were obtained and analyzed using algorithms previously described [20, 21]. Briefly, DAPI staining was used to generate a total tissue mask. The S100 (Cy3) signal was used to generate a tumor mask. A rapid exponential subtraction algorithm was used to subtract out-of-focus information and each pixel was assigned to a tumor or stroma compartment. Gp100 (Cy5) signal intensity was calculated as an average signal of the pixels comprising the tumor compartment. Histospots containing insufficient tissue (< 3% of the core area) or abundant necrotic tissue were excluded. Linear regression was performed to assess correlation between control specimens represented on both arrays, and the resulting equation was used to compute adjusted scores for the melanoma array.

Results

gp100 expression in melanoma cell lines

We first compared expression of gp100 in a panel of 8 uveal and 10 cutaneous melanoma cell lines by Western blot and calculated band intensity relative to loading control. Strong gp100 expression (relative intensity > 20) was observed in 7/8 (88%) uveal melanoma cell lines and 4/10 (40%) cutaneous melanoma cell lines (Fig. 1A, S1). The highest gp100 expression was observed in the cutaneous line YUKRIN. Although the small sample size prevented robust statistical analysis, mean gp100 expression was similar in cutaneous and uveal melanoma, yet expression levels were more variable in cutaneous lines, which exhibited a mean relative intensity of 41.3 and standard deviation of 58.8. Expression in uveal melanoma exhibited a mean relative intensity of 37.3 and standard deviation of 27.1. Thus, it appears that uveal melanoma cell lines express more consistently high levels of gp100, while cutaneous lines represent a diverse range.Fig. 1 Detection of gp100 protein in melanoma cell lines and tissues. A Western blot showing expression of gp100 (100kD) in cell lines derived from cutaneous and uveal melanoma cell lines (left). Pixel intensity was quantitated for each band using ImageJ and displayed relative to loading control (right). “Strong expression” was defined as relative intensity > 20 and indicated by dashed line. Blue, cutaneous melanoma-derived; red, uveal melanoma-derived. B Representative images from immunohistochemical staining of the nevus and melanoma tissue microarrays showing scores from 0 to 3. Top left, nevus; top right, primary melanoma, lower left, metastatic melanoma; lower right, metastatic melanoma. C Intensity scores for nevus and melanoma tissue microarrays. *p < 0.01, ****p < 0.0001

gp100 expression in human tumors by immunohistochemistry

We performed IHC in two tissue microarrays (TMAs), one consisting of 119 primary melanomas and 210 metastases, and a second consisting of 252 nevi. Figure 1B shows examples of positive and negative gp100 immunoreactivity in representative cores. Less than 50% of benign nevi exhibited moderate or strong gp100 expression, whereas > 80% of melanomas were either moderately or strongly positive (Fig. 1C). Strong expression was most prevalent in metastases (43% vs 26% in primary tumors).

gp100 expression and associations with clinical characteristics

The melanomas were annotated for clinical characteristics. No clear association was found within either the primary or metastatic cohorts between the degree of gp100 immunoreactivity and overall survival. Similarly, no association was found between gp100 intensity and clinical or pathological characteristics (depth, ulceration, mitoses, gender or age among primary melanomas and BRAF status, gender or age within the metastatic disease cohort).

Quantitative immunofluorescence measures of gp100 expression

Given that the naked eye cannot distinguish small differences in intensity, we used quantitative immunofluorescence (QIF) to better appreciate the range of gp100 expression in cutaneous melanoma. This method correlates well with expression as measured by other methods [20]. QIF staining is depicted in Fig. 2A. The two TMAs contained matching histospots from the same tumor. QIF scores were highly correlated in matching spots (r = 0.9, Fig. S2), although staining on the melanoma array was somewhat weaker, likely due to age of the section. Scores for the melanoma array were therefore normalized to the nevus array. QIF scores ranged from 1000 to 17,000. Importantly, QIF scores correlated well with the IHC scores (p < 0.0001), but within each IHC group (weak, moderate or strong staining) there was substantial variability (Fig. 2B). As with the IHC, gp100 expression as quantified by QIF in melanomas was significantly higher than nevi and higher in metastases than primary lesions (p < 0.0001 and p = 0.03, respectively; Fig. 2C). As gp100-targeting therapeutics are being investigated for patients with metastatic cutaneous melanoma, we note that while these specimens almost universally expressed gp100, expression levels were quite variable (Fig. 2C).Fig. 2 Immunofluorescence staining of gp100 in melanoma tissues. A Representative pseudo-color images for two metastatic melanoma histospots with high (top) and low (bottom) IF intensity scores. Staining target is indicated in lower right for each image. Tumor masks generated from analysis of S100 staining are shown for each histospot, and IF intensity score is determined for gp100 in the tumor compartment. B Box plot showing IF scores from histospots that received both a QIF score and an IHC score (Fig. 1). Histospots were grouped by IHC score as indicated. ****p < 0.0001. C Box plot showing IF scores for nevi, primary melanomas, and metastatic melanomas. *p < 0.01, ****p < 0.0001

Discussion

Gp100 is emerging as an important target in melanoma given its specificity for melanocytes. Tebentafusp represents a major advancement in the treatment of uveal melanoma, and initial trials in cutaneous melanoma have yielded promising results [13]. Along with ongoing phase 3 studies of tebentafusp, other gp100-targeted treatment modalities are being studied for melanoma patients, including alternative bi-specific antibodies and cell therapy approaches. However, an association between gp100 levels and response to these treatments has not been established. We report moderate or strong gp100 expression in over 80% of cutaneous melanomas in our cohort, supporting further investigation of gp100 targeted agents in this population. Further, we observed variability in the degree of gp100 expression in both primary and metastatic melanomas, provoking consideration of whether patient stratification according to gp100 expression could refine the target population for these treatments and improve response rates. The findings herein expand on previous reports describing heterogeneous gp100 expression and correlation with disease stage by utilizing a larger cohort and quantitative methods revealing a broad range of expression even among metastatic lesions.

Numerous gp100 targeted adoptive cell therapies [22] and vaccines [10, 11] have been investigated in clinical trials, and these strategies continue to be explored using more contemporary strategies. The peptide vaccine Gp-100:209-217 improved the response rate of interleukin-2 in a Phase III trial, but did not yield a statistically significant survival benefit and is therefore not approved [23]. Cellular therapies have also been designed to target gp100. For example, a small phase II trial of TCR engineered lymphocytes targeting gp100 was conducted (NCT00509496) and responses were observed in a subset of patients [24]. Oncolytic viruses binding gp100 positive cells have also been studied (NCT01008527). A role for gp100 expression in therapeutic response has not been established, but it is possible that lack of baseline expression or loss of expression of gp100 with time may emerge as a mechanism of resistance to gp100 targeting therapies [25]. Importantly, while the present study describes variability in gp100 expression between patients, cores may not represent the entire specimen and we are therefore unable to assess intratumoral heterogeneity. We note that in clinical practice, biomarker analysis for metastatic patients is typically done using core biopsies of similar diameter to tissue microarray cores. Additional studies are needed on whole tumor resection specimens to determine whether there is heterogenous expression within a tumor. Such intratumoral heterogeneity may suggest mechanisms of treatment resistance, such as outgrowth of low antigen expressing tumor cells.

While the significance of gp100 expression levels in predicting response to gp100 targeted agents remains to be investigated, correlation of target expression with therapeutic response is well documented in other settings. For example, numerous studies in HER2 + breast cancer patients have demonstrated differential response to anti-Her2/Neu antibodies based on target expression levels [26]. Tebentafusp represents an attractive strategy for managing subsets of cutaneous melanomas that have progressed on ICI regimens. As ongoing trials evaluate tebentafusp in cutaneous melanoma patients following disease progression on anti-PD1 therapy (NCT05549297), it will be critical to determine whether there is a threshold for gp100 expression below which patients are unlikely to respond. This will enable clinicians to direct these patients to alternative therapies. Further, eligibility for tebentafusp is HLA-restricted, and as similar agents are developed using less common HLA types, insights into patient stratification gained from tebentafusp studies will be valuable.

Although tebentafusp is the first FDA-approved gp100 targeted therapy, new molecular and cellular technologies are emerging and tumor-specific targets to which antibodies and cells can bind, such as gp100, are important for minimizing off-target effects. Here we show that while some expression of gp100 is seen in most metastatic cutaneous melanomas, the degree of expression is variable. It is possible that responses are only seen when the target is expressed at higher levels, and our results suggest that quantitative measures of gp100 should be incorporated into clinical trials with gp100 targeting antibodies or cellular products.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file 1. Fig. S1 Western blot analysis of additional cutaneous melanoma cell lines. Fig. S2 Correlation of IF scores for matched histospots on nevus and melanoma TMAs. (PDF 582 kb)

Supplementary file 2. (XLSX 10 kb)

Author contributions

J.E.M., D.G.S., and D.D. performed experiments. J.E.M. prepared figures. A.J.A., N.H., and J.E.M collected data. H.M.K. and K.S.M.S provided resources. H.M.K provided supervision and conceptualization. J.E.M and H.E.K. wrote the manuscript text. All authors reviewed the manuscript.

Funding

This work was supported by NIH grants P50 CA121974, 1R01CA269349, and 1R01CA269286 (H.M.K.) and by the Yale Human and Translational Immunology Training Program through grant 1T32AI155387-01A1 (J.E.M.).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Conflict of interest

H.M.K. holds Consulting or Advisory Roles with Iovance Biotherapeutics, Merck, Clinigen Group, Bristol Myers Squibb, ChemoCentryx, Signatera, Gigagen, GI Reviewers, Seranova Bio, Pliant, Eisai, Invox, Werewolf Pharma, has received research funding from Merck (Inst), Bristol Myers Squibb (Inst), Apexigen (Inst), and has received travel, accomodations, or expenses from Apexigen. No other potential competing interests were reported.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Singh AD Turell ME Topham AK Uveal melanoma: trends in incidence, treatment, and survival Ophthalmology 2011 118 9 1881 1885 10.1016/j.ophtha.2011.01.040 21704381
Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118(9):1881–188521704381 10.1016/j.ophtha.2011.01.040
2. Jager MJ Uveal melanoma Nat Rev Dis Primers 2020 6 1 24 10.1038/s41572-020-0158-0 32273508
Jager MJ et al (2020) Uveal melanoma. Nat Rev Dis Primers 6(1):2432273508 10.1038/s41572-020-0158-0
3. Middleton MR Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma Clin Cancer Res 2020 26 22 5869 5878 10.1158/1078-0432.CCR-20-1247 32816891
Middleton MR et al (2020) Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 26(22):5869–587832816891 10.1158/1078-0432.CCR-20-1247
4. Szeligo BM Ivey AD Boone BA Poor response to checkpoint immunotherapy in uveal melanoma highlights the persistent need for innovative regional therapy approaches to manage liver metastases Cancers (Basel) 2021 13 14 3426 10.3390/cancers13143426 34298647
Szeligo BM, Ivey AD, Boone BA (2021) Poor response to checkpoint immunotherapy in uveal melanoma highlights the persistent need for innovative regional therapy approaches to manage liver metastases. Cancers (Basel) 13(14):342634298647 10.3390/cancers13143426
5. Hilke FJ Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients Cancers (Basel) 2020 12 9 2356 10.3390/cancers12092359 32825402
Hilke FJ et al (2020) Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients. Cancers (Basel) 12(9):235632825402 10.3390/cancers12092359
6. de Vries TJ High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma Br J Cancer 1998 78 9 1156 1161 10.1038/bjc.1998.646 9820172
de Vries TJ et al (1998) High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer 78(9):1156–11619820172 10.1038/bjc.1998.646
7. Wagner SN Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy Cancer Immunol Immunother 1997 44 4 239 247 10.1007/s002620050379 9222283
Wagner SN et al (1997) Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Cancer Immunol Immunother 44(4):239–2479222283 10.1007/s002620050379
8. Hodi FS Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 2010 363 8 711 723 10.1056/NEJMoa1003466 20525992
Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–72320525992 10.1056/NEJMoa1003466
9. Dillman RO An update on the relevance of vaccine research for the treatment of metastatic melanoma Melanoma Manag 2017 4 4 203 215 10.2217/mmt-2017-0021 30190926
Dillman RO (2017) An update on the relevance of vaccine research for the treatment of metastatic melanoma. Melanoma Manag 4(4):203–21530190926 10.2217/mmt-2017-0021
10. Martinez-Perez D Gp-100 as a novel therapeutic target in uveal melanoma Cancers (Basel) 2021 13 23 5968 10.3390/cancers13235968 34885078
Martinez-Perez D et al (2021) Gp-100 as a novel therapeutic target in uveal melanoma. Cancers (Basel) 13(23):596834885078 10.3390/cancers13235968
11. Nathan P Overall survival benefit with tebentafusp in metastatic uveal melanoma N Engl J Med 2021 385 13 1196 1206 10.1056/NEJMoa2103485 34551229
Nathan P et al (2021) Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 385(13):1196–120634551229 10.1056/NEJMoa2103485
12. Montazeri K Pattanayak V Sullivan RJ Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations Drug Des Dev Ther 2023 17 333 339 10.2147/DDDT.S368954
Montazeri K, Pattanayak V, Sullivan RJ (2023) Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations. Drug Des Dev Ther 17:333–33910.2147/DDDT.S368954
13. Hamid O Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study J Immunother Cancer 2023 11 6 e006747 10.1136/jitc-2023-006747 37286303
Hamid O et al (2023) Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J Immunother Cancer 11(6):e00674737286303 10.1136/jitc-2023-006747
14. Larkin J Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma N Engl J Med 2019 381 16 1535 1546 10.1056/NEJMoa1910836 31562797
Larkin J et al (2019) Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–154631562797 10.1056/NEJMoa1910836
15. Hamid O Five-year survival outcomes for patients with advanced melanoma treated with Pembrolizumab in KEYNOTE-001 Ann Oncol 2019 30 4 582 588 10.1093/annonc/mdz011 30715153
Hamid O et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with Pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582–58830715153 10.1093/annonc/mdz011
16. Halaban R PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Pigment Cell Melanoma Res 2010 23 2 190 200 10.1111/j.1755-148X.2010.00685.x 20149136
Halaban R et al (2010) PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23(2):190–20020149136 10.1111/j.1755-148X.2010.00685.x
17. Kluger HM Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites Clin Cancer Res 2015 21 13 3052 3060 10.1158/1078-0432.CCR-14-3073 25788491
Kluger HM et al (2015) Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 21(13):3052–306025788491 10.1158/1078-0432.CCR-14-3073
18. Berger AJ Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival Cancer Res 2003 63 23 8103 8107 14678960
Berger AJ et al (2003) Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 63(23):8103–810714678960
19. Su DG Melanocortin-1 receptor expression as a marker of progression in melanoma JCO Precis Oncol 2024 8 e2300702 10.1200/PO.23.00702 38662983
Su DG et al (2024) Melanocortin-1 receptor expression as a marker of progression in melanoma. JCO Precis Oncol 8:e230070238662983 10.1200/PO.23.00702
20. Camp RL Chung GG Rimm DL Automated subcellular localization and quantification of protein expression in tissue microarrays Nat Med 2002 8 11 1323 1327 10.1038/nm791 12389040
Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8(11):1323–132712389040 10.1038/nm791
21. Rubin MA Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements Am J Pathol 2004 164 3 831 840 10.1016/S0002-9440(10)63171-9 14982837
Rubin MA et al (2004) Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 164(3):831–84014982837 10.1016/S0002-9440(10)63171-9
22. Simon B Arming T cells with a gp100-specific TCR and a CSPG4-specific CAR using combined DNA- and RNA-based receptor transfer Cancers (Basel) 2019 11 5 696 10.3390/cancers11050696 31137488
Simon B et al (2019) Arming T cells with a gp100-specific TCR and a CSPG4-specific CAR using combined DNA- and RNA-based receptor transfer. Cancers (Basel) 11(5):69631137488 10.3390/cancers11050696
23. Schwartzentruber DJ gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 2011 364 22 2119 2127 10.1056/NEJMoa1012863 21631324
Schwartzentruber DJ et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364(22):2119–212721631324 10.1056/NEJMoa1012863
24. Yao X Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer Blood 2012 119 24 5688 5696 10.1182/blood-2011-10-386482 22555974
Yao X et al (2012) Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119(24):5688–569622555974 10.1182/blood-2011-10-386482
25. Chandran SS Klebanoff CA T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance Immunol Rev 2019 290 1 127 147 10.1111/imr.12772 31355495
Chandran SS, Klebanoff CA (2019) T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev 290(1):127–14731355495 10.1111/imr.12772
26. Atallah NM Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level Br J Cancer 2023 129 10 1692 1705 10.1038/s41416-023-02426-4 37740038
Atallah NM et al (2023) Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level. Br J Cancer 129(10):1692–170537740038 10.1038/s41416-023-02426-4
